nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—ORM1—bile—bile duct cancer	0.0973	0.233	CbGeAlD
Tacrolimus—ABCA5—pancreas—bile duct cancer	0.0354	0.0849	CbGeAlD
Tacrolimus—ORM1—gall bladder—bile duct cancer	0.027	0.0647	CbGeAlD
Tacrolimus—PPP3CA—pancreas—bile duct cancer	0.0239	0.0573	CbGeAlD
Tacrolimus—ALB—gall bladder—bile duct cancer	0.0237	0.0568	CbGeAlD
Tacrolimus—ABCA5—liver—bile duct cancer	0.0225	0.054	CbGeAlD
Tacrolimus—MTOR—pancreas—bile duct cancer	0.0177	0.0424	CbGeAlD
Tacrolimus—ABCA5—lymph node—bile duct cancer	0.0173	0.0414	CbGeAlD
Tacrolimus—FKBP1A—pancreas—bile duct cancer	0.0159	0.0381	CbGeAlD
Tacrolimus—PPP3CA—liver—bile duct cancer	0.0152	0.0365	CbGeAlD
Tacrolimus—CYP3A7—liver—bile duct cancer	0.0125	0.03	CbGeAlD
Tacrolimus—PPP3CA—lymph node—bile duct cancer	0.0117	0.028	CbGeAlD
Tacrolimus—MTOR—liver—bile duct cancer	0.0112	0.027	CbGeAlD
Tacrolimus—CYP3A7-CYP3A51P—liver—bile duct cancer	0.0106	0.0255	CbGeAlD
Tacrolimus—FKBP1A—liver—bile duct cancer	0.0101	0.0242	CbGeAlD
Tacrolimus—MTOR—lymph node—bile duct cancer	0.00862	0.0207	CbGeAlD
Tacrolimus—ORM1—liver—bile duct cancer	0.00792	0.019	CbGeAlD
Tacrolimus—FKBP1A—lymph node—bile duct cancer	0.00775	0.0186	CbGeAlD
Tacrolimus—ALB—liver—bile duct cancer	0.00694	0.0166	CbGeAlD
Tacrolimus—CYP3A5—pancreas—bile duct cancer	0.00692	0.0166	CbGeAlD
Tacrolimus—ORM1—lymph node—bile duct cancer	0.00607	0.0146	CbGeAlD
Tacrolimus—ALB—lymph node—bile duct cancer	0.00532	0.0128	CbGeAlD
Tacrolimus—CYP3A5—liver—bile duct cancer	0.0044	0.0106	CbGeAlD
Tacrolimus—ABCB1—pancreas—bile duct cancer	0.00368	0.00881	CbGeAlD
Tacrolimus—CYP3A4—liver—bile duct cancer	0.0033	0.00792	CbGeAlD
Tacrolimus—ABCB1—liver—bile duct cancer	0.00234	0.00561	CbGeAlD
Tacrolimus—ABCB1—lymph node—bile duct cancer	0.00179	0.0043	CbGeAlD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—EGFR—bile duct cancer	0.000684	0.00117	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—bile duct cancer	0.000677	0.00116	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by VEGF—HRAS—bile duct cancer	0.000676	0.00116	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—KRAS—bile duct cancer	0.000676	0.00116	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—EGFR—bile duct cancer	0.000673	0.00116	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by Insulin receptor—HRAS—bile duct cancer	0.000671	0.00115	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—NRAS—bile duct cancer	0.000654	0.00112	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—NRAS—bile duct cancer	0.000654	0.00112	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—bile duct cancer	0.000654	0.00112	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—NRAS—bile duct cancer	0.000648	0.00111	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by VEGF—IL6—bile duct cancer	0.000647	0.00111	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—KRAS—bile duct cancer	0.000646	0.00111	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—EGFR—bile duct cancer	0.000643	0.0011	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—NRAS—bile duct cancer	0.000643	0.0011	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by Insulin receptor—IL6—bile duct cancer	0.000642	0.0011	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—EGFR—bile duct cancer	0.00064	0.0011	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—bile duct cancer	0.00064	0.0011	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—NRAS—bile duct cancer	0.00064	0.0011	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—bile duct cancer	0.000639	0.0011	CbGpPWpGaD
Tacrolimus—MTOR—Disease—IDH1—bile duct cancer	0.000638	0.00109	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—EGFR—bile duct cancer	0.000637	0.00109	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—KRAS—bile duct cancer	0.000636	0.00109	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—EGFR—bile duct cancer	0.000634	0.00109	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—FAR2—bile duct cancer	0.000625	0.00107	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—bile duct cancer	0.000625	0.00107	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—bile duct cancer	0.000622	0.00107	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—HGF—bile duct cancer	0.000614	0.00105	CbGpPWpGaD
Tacrolimus—ALB—Vitamin B12 Metabolism—IL6—bile duct cancer	0.000609	0.00105	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—KRAS—bile duct cancer	0.000607	0.00104	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—NRAS—bile duct cancer	0.000606	0.00104	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—bile duct cancer	0.000604	0.00104	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—KRAS—bile duct cancer	0.000604	0.00104	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—TGFBR2—bile duct cancer	0.000603	0.00103	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—KRAS—bile duct cancer	0.000602	0.00103	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—KRAS—bile duct cancer	0.000599	0.00103	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—bile duct cancer	0.000596	0.00102	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—EGFR—bile duct cancer	0.000596	0.00102	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—EGFR—bile duct cancer	0.000596	0.00102	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—EGFR—bile duct cancer	0.000591	0.00101	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—bile duct cancer	0.00059	0.00101	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	0.00059	0.00101	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—ERBB2—bile duct cancer	0.000586	0.00101	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—EGFR—bile duct cancer	0.000586	0.001	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—EGFR—bile duct cancer	0.000583	0.001	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—NRAS—bile duct cancer	0.000583	0.001	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—bile duct cancer	0.00058	0.000994	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—HRAS—bile duct cancer	0.000574	0.000985	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—SMAD4—bile duct cancer	0.000571	0.000979	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—bile duct cancer	0.000568	0.000975	CbGpPWpGaD
Tacrolimus—MTOR—BDNF signaling pathway—HRAS—bile duct cancer	0.000565	0.000969	CbGpPWpGaD
Tacrolimus—ALB—Platelet degranulation—TGFB1—bile duct cancer	0.000564	0.000967	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—bile duct cancer	0.000563	0.000966	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—KRAS—bile duct cancer	0.000563	0.000966	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—KRAS—bile duct cancer	0.000563	0.000966	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—KRAS—bile duct cancer	0.000558	0.000958	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—KRAS—bile duct cancer	0.000553	0.000949	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—EGFR—bile duct cancer	0.000552	0.000946	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—KRAS—bile duct cancer	0.000551	0.000945	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—IL6—bile duct cancer	0.00055	0.000943	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—HRAS—bile duct cancer	0.000549	0.000943	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—NOS2—bile duct cancer	0.000548	0.00094	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—FAR2—bile duct cancer	0.000548	0.00094	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TGFBR2—bile duct cancer	0.000545	0.000934	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—TP53—bile duct cancer	0.000541	0.000929	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—HRAS—bile duct cancer	0.000541	0.000928	CbGpPWpGaD
Tacrolimus—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—bile duct cancer	0.000537	0.000922	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—EGFR—bile duct cancer	0.000531	0.000911	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—bile duct cancer	0.000528	0.000906	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—IL6—bile duct cancer	0.000526	0.000902	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—GNAS—bile duct cancer	0.000525	0.000901	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—KRAS—bile duct cancer	0.000521	0.000894	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—RNF43—bile duct cancer	0.00052	0.000892	CbGpPWpGaD
Tacrolimus—MTOR—Insulin Signaling—HRAS—bile duct cancer	0.000519	0.00089	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—IL6—bile duct cancer	0.000517	0.000888	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—HRAS—bile duct cancer	0.000516	0.000886	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—SMAD4—bile duct cancer	0.000516	0.000884	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—bile duct cancer	0.000514	0.000882	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—HRAS—bile duct cancer	0.000514	0.000882	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—HRAS—bile duct cancer	0.000511	0.000877	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—HRAS—bile duct cancer	0.000509	0.000873	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—KRAS—bile duct cancer	0.000502	0.000861	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—bile duct cancer	0.000501	0.00086	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—TGFB1—bile duct cancer	0.000499	0.000856	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—bile duct cancer	0.000499	0.000856	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—IL6—bile duct cancer	0.000496	0.00085	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—IL6—bile duct cancer	0.000494	0.000848	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—IL6—bile duct cancer	0.000492	0.000844	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—IDH2—bile duct cancer	0.000491	0.000842	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—IL6—bile duct cancer	0.000489	0.00084	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—IL6—bile duct cancer	0.000487	0.000835	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—HRAS—bile duct cancer	0.000479	0.000821	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—bile duct cancer	0.000479	0.000821	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—HRAS—bile duct cancer	0.000479	0.000821	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—HRAS—bile duct cancer	0.000474	0.000814	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—HRAS—bile duct cancer	0.00047	0.000807	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—HRAS—bile duct cancer	0.000468	0.000803	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—IL6—bile duct cancer	0.000458	0.000786	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—bile duct cancer	0.000458	0.000786	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—IL6—bile duct cancer	0.000458	0.000786	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—IL6—bile duct cancer	0.000454	0.000779	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—IL6—bile duct cancer	0.00045	0.000772	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—IL6—bile duct cancer	0.000448	0.000769	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—ERBB2—bile duct cancer	0.000446	0.000766	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—NRAS—bile duct cancer	0.000446	0.000765	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—HRAS—bile duct cancer	0.000443	0.00076	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—HRAS—bile duct cancer	0.000426	0.000732	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—NOS2—bile duct cancer	0.000425	0.000729	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—bile duct cancer	0.000424	0.000727	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TGFBR2—bile duct cancer	0.000422	0.000725	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—IDH1—bile duct cancer	0.000422	0.000724	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—ERBB2—bile duct cancer	0.000412	0.000707	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—IL6—bile duct cancer	0.000408	0.0007	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—GNAS—bile duct cancer	0.000407	0.000699	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—EGFR—bile duct cancer	0.000406	0.000697	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—bile duct cancer	0.000406	0.000696	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—PTGS2—bile duct cancer	0.000403	0.000691	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—SMAD4—bile duct cancer	0.0004	0.000686	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—IL6—bile duct cancer	0.000394	0.000675	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—KRAS—bile duct cancer	0.000384	0.000658	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—NRAS—bile duct cancer	0.000372	0.000638	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC5A5—bile duct cancer	0.00037	0.000635	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—TP53—bile duct cancer	0.000364	0.000624	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—IDH2—bile duct cancer	0.000355	0.000608	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—bile duct cancer	0.000348	0.000598	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bile duct cancer	0.000341	0.000584	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—NRAS—bile duct cancer	0.00034	0.000583	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TGFBR2—bile duct cancer	0.000339	0.000582	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—EGFR—bile duct cancer	0.000339	0.000581	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—FAR2—bile duct cancer	0.000338	0.000579	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HGF—bile duct cancer	0.000338	0.000579	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—ERBB2—bile duct cancer	0.000334	0.000573	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—IL6—bile duct cancer	0.000333	0.000571	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—GNAS—bile duct cancer	0.000332	0.00057	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—HRAS—bile duct cancer	0.000326	0.000559	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC5A5—bile duct cancer	0.000324	0.000556	CbGpPWpGaD
Tacrolimus—MTOR—Disease—SMAD4—bile duct cancer	0.000321	0.000551	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—ERBB2—bile duct cancer	0.000321	0.000551	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—KRAS—bile duct cancer	0.00032	0.000549	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—ERBB2—bile duct cancer	0.00032	0.000548	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—HGF—bile duct cancer	0.000316	0.000543	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—NRAS—bile duct cancer	0.000313	0.000538	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PTGS2—bile duct cancer	0.000312	0.000536	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—IL6—bile duct cancer	0.000312	0.000535	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—EGFR—bile duct cancer	0.000309	0.000531	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—IDH2—bile duct cancer	0.000305	0.000524	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—IDH1—bile duct cancer	0.000305	0.000523	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—KRAS—bile duct cancer	0.000292	0.000501	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—TGFB1—bile duct cancer	0.000291	0.0005	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—ERBB2—bile duct cancer	0.000289	0.000495	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—GNAS—bile duct cancer	0.000287	0.000493	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—EGFR—bile duct cancer	0.000286	0.00049	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—SLC5A5—bile duct cancer	0.000278	0.000477	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—HRAS—bile duct cancer	0.000272	0.000466	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—KRAS—bile duct cancer	0.00027	0.000463	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—IDH2—bile duct cancer	0.000268	0.000459	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—IDH1—bile duct cancer	0.000263	0.000451	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—IL6—bile duct cancer	0.00026	0.000446	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—NRAS—bile duct cancer	0.000254	0.000436	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—GNAS—bile duct cancer	0.000252	0.000432	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—TGFB1—bile duct cancer	0.00025	0.000429	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HRAS—bile duct cancer	0.000248	0.000426	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MMP9—bile duct cancer	0.000248	0.000425	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	0.000246	0.000423	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—NRAS—bile duct cancer	0.000244	0.000419	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—NRAS—bile duct cancer	0.000243	0.000417	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—NOS2—bile duct cancer	0.000243	0.000416	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	0.000241	0.000414	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NOS2—bile duct cancer	0.000239	0.00041	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL6—bile duct cancer	0.000238	0.000408	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TGFBR2—bile duct cancer	0.000238	0.000407	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—EGFR—bile duct cancer	0.000232	0.000397	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—IDH1—bile duct cancer	0.00023	0.000395	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—HRAS—bile duct cancer	0.000229	0.000393	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—GNAS—bile duct cancer	0.000229	0.000393	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	0.000228	0.000391	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—TGFB1—bile duct cancer	0.000226	0.000388	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SMAD4—bile duct cancer	0.000225	0.000386	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—ERBB2—bile duct cancer	0.000224	0.000384	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—EGFR—bile duct cancer	0.000222	0.000382	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—EGFR—bile duct cancer	0.000221	0.00038	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—NRAS—bile duct cancer	0.00022	0.000377	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—IL6—bile duct cancer	0.00022	0.000377	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—KRAS—bile duct cancer	0.000219	0.000375	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GNAS—bile duct cancer	0.000216	0.000371	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—KRAS—bile duct cancer	0.00021	0.00036	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—KRAS—bile duct cancer	0.000209	0.000359	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TGFB1—bile duct cancer	0.000204	0.00035	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	0.000203	0.000348	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—SLC5A5—bile duct cancer	0.000201	0.000345	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—EGFR—bile duct cancer	0.0002	0.000343	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—ERBB2—bile duct cancer	0.000195	0.000334	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MMP9—bile duct cancer	0.000192	0.000329	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—KRAS—bile duct cancer	0.000189	0.000324	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—HRAS—bile duct cancer	0.000186	0.000319	CbGpPWpGaD
Tacrolimus—MTOR—Disease—ERBB2—bile duct cancer	0.00018	0.000308	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HRAS—bile duct cancer	0.000179	0.000306	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—IL6—bile duct cancer	0.000178	0.000305	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—HRAS—bile duct cancer	0.000178	0.000305	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTGS2—bile duct cancer	0.000176	0.000301	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—SLC5A5—bile duct cancer	0.000173	0.000297	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—NRAS—bile duct cancer	0.00017	0.000292	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—IL6—bile duct cancer	0.00017	0.000292	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TP53—bile duct cancer	0.000168	0.000288	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—IDH2—bile duct cancer	0.000165	0.000283	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	0.000162	0.000279	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—HRAS—bile duct cancer	0.000161	0.000276	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TGFB1—bile duct cancer	0.000158	0.000271	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GNAS—bile duct cancer	0.000156	0.000268	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—EGFR—bile duct cancer	0.000155	0.000266	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL6—bile duct cancer	0.000154	0.000264	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SLC5A5—bile duct cancer	0.000152	0.00026	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—NRAS—bile duct cancer	0.000148	0.000254	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—KRAS—bile duct cancer	0.000147	0.000251	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—IDH1—bile duct cancer	0.000142	0.000243	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—NRAS—bile duct cancer	0.000139	0.000238	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NRAS—bile duct cancer	0.000137	0.000235	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EGFR—bile duct cancer	0.000135	0.000231	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GNAS—bile duct cancer	0.000135	0.000231	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—bile duct cancer	0.00013	0.000223	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TGFB1—bile duct cancer	0.000129	0.000221	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—KRAS—bile duct cancer	0.000127	0.000219	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TGFB1—bile duct cancer	0.000127	0.000218	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ERBB2—bile duct cancer	0.000126	0.000216	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EGFR—bile duct cancer	0.000125	0.000214	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—HRAS—bile duct cancer	0.000125	0.000214	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—KRAS—bile duct cancer	0.000119	0.000205	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL6—bile duct cancer	0.000119	0.000204	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GNAS—bile duct cancer	0.000118	0.000202	CbGpPWpGaD
Tacrolimus—MTOR—Disease—KRAS—bile duct cancer	0.000118	0.000202	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTGS2—bile duct cancer	0.000116	0.000199	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HRAS—bile duct cancer	0.000108	0.000186	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MMP9—bile duct cancer	0.000108	0.000185	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—bile duct cancer	0.000106	0.000182	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL6—bile duct cancer	0.000104	0.000178	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—HRAS—bile duct cancer	0.000102	0.000174	CbGpPWpGaD
Tacrolimus—MTOR—Disease—HRAS—bile duct cancer	0.0001	0.000172	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NRAS—bile duct cancer	9.57e-05	0.000164	CbGpPWpGaD
Tacrolimus—MTOR—Disease—IL6—bile duct cancer	9.57e-05	0.000164	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SLC5A5—bile duct cancer	9.35e-05	0.00016	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TGFB1—bile duct cancer	8.9e-05	0.000153	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EGFR—bile duct cancer	8.72e-05	0.00015	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTGS2—bile duct cancer	8.4e-05	0.000144	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KRAS—bile duct cancer	8.24e-05	0.000141	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—bile duct cancer	7.32e-05	0.000126	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GNAS—bile duct cancer	7.27e-05	0.000125	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTGS2—bile duct cancer	7.23e-05	0.000124	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HRAS—bile duct cancer	7e-05	0.00012	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL6—bile duct cancer	6.7e-05	0.000115	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTGS2—bile duct cancer	6.33e-05	0.000109	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTGS2—bile duct cancer	3.9e-05	6.7e-05	CbGpPWpGaD
